Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity
Compound 5-{[(2E)-3-bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic acid (<b>C1</b>), a new 5-aminosalicylic acid (5-ASA) derivative, has proven to be an antioxidant in vitro and an anti-inflammatory agent in mice. The in vivo inhibition of myeloperoxidase was comparable to that of i...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a964201dc07d49c3a8486aaa6196e02a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a964201dc07d49c3a8486aaa6196e02a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a964201dc07d49c3a8486aaa6196e02a2021-11-25T18:27:21ZPreclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity10.3390/molecules262268011420-3049https://doaj.org/article/a964201dc07d49c3a8486aaa6196e02a2021-11-01T00:00:00Zhttps://www.mdpi.com/1420-3049/26/22/6801https://doaj.org/toc/1420-3049Compound 5-{[(2E)-3-bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic acid (<b>C1</b>), a new 5-aminosalicylic acid (5-ASA) derivative, has proven to be an antioxidant in vitro and an anti-inflammatory agent in mice. The in vivo inhibition of myeloperoxidase was comparable to that of indomethacin. The aim of this study was to take another step in the preclinical evaluation of <b>C1</b> by examining acute toxicity with the up-and-down OECD method and pharmacokinetic profiles by administration of the compound to Wistar rats through intravenous (i.v.), oral (p.o.), and intraperitoneal (i.p.) routes. According to the Globally Harmonized System, <b>C1</b> belongs to categories 4 and 5 for the i.p. and p.o. routes, respectively. An RP-HPLC method for <b>C1</b> quantification in plasma was successfully validated. Regarding the pharmacokinetic profile, the elimination half-life was approximately 0.9 h with a clearance of 24 mL/min after i.v. administration of <b>C1</b> (50 mg/kg). After p.o. administration (50 mg/kg), the maximum plasma concentration was reached at 33 min, the oral bioavailability was about 77%, and the compound was amply distributed to all tissues evaluated. Therefore, <b>C1</b> administered p.o. in rats is suitable for reaching the colon where it can exert its effect, suggesting an important advantage over 5-ASA and indomethacin in treating ulcerative colitis and Crohn’s disease.Mara Gutiérrez-SánchezAurelio Romero-CastroJosé Correa-BasurtoMartha Cecilia Rosales-HernándezItzia Irene Padilla-MartínezJessica Elena Mendieta-WejebeMDPI AGarticle5-5-{[(2E)-3-bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic acid (<b>C1</b>)aminosalicylic acidRP-HPLCpharmacokineticsulcerative colitisCrohn’s diseaseOrganic chemistryQD241-441ENMolecules, Vol 26, Iss 6801, p 6801 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
5-5-{[(2E)-3-bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic acid (<b>C1</b>) aminosalicylic acid RP-HPLC pharmacokinetics ulcerative colitis Crohn’s disease Organic chemistry QD241-441 |
| spellingShingle |
5-5-{[(2E)-3-bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic acid (<b>C1</b>) aminosalicylic acid RP-HPLC pharmacokinetics ulcerative colitis Crohn’s disease Organic chemistry QD241-441 Mara Gutiérrez-Sánchez Aurelio Romero-Castro José Correa-Basurto Martha Cecilia Rosales-Hernández Itzia Irene Padilla-Martínez Jessica Elena Mendieta-Wejebe Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity |
| description |
Compound 5-{[(2E)-3-bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic acid (<b>C1</b>), a new 5-aminosalicylic acid (5-ASA) derivative, has proven to be an antioxidant in vitro and an anti-inflammatory agent in mice. The in vivo inhibition of myeloperoxidase was comparable to that of indomethacin. The aim of this study was to take another step in the preclinical evaluation of <b>C1</b> by examining acute toxicity with the up-and-down OECD method and pharmacokinetic profiles by administration of the compound to Wistar rats through intravenous (i.v.), oral (p.o.), and intraperitoneal (i.p.) routes. According to the Globally Harmonized System, <b>C1</b> belongs to categories 4 and 5 for the i.p. and p.o. routes, respectively. An RP-HPLC method for <b>C1</b> quantification in plasma was successfully validated. Regarding the pharmacokinetic profile, the elimination half-life was approximately 0.9 h with a clearance of 24 mL/min after i.v. administration of <b>C1</b> (50 mg/kg). After p.o. administration (50 mg/kg), the maximum plasma concentration was reached at 33 min, the oral bioavailability was about 77%, and the compound was amply distributed to all tissues evaluated. Therefore, <b>C1</b> administered p.o. in rats is suitable for reaching the colon where it can exert its effect, suggesting an important advantage over 5-ASA and indomethacin in treating ulcerative colitis and Crohn’s disease. |
| format |
article |
| author |
Mara Gutiérrez-Sánchez Aurelio Romero-Castro José Correa-Basurto Martha Cecilia Rosales-Hernández Itzia Irene Padilla-Martínez Jessica Elena Mendieta-Wejebe |
| author_facet |
Mara Gutiérrez-Sánchez Aurelio Romero-Castro José Correa-Basurto Martha Cecilia Rosales-Hernández Itzia Irene Padilla-Martínez Jessica Elena Mendieta-Wejebe |
| author_sort |
Mara Gutiérrez-Sánchez |
| title |
Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity |
| title_short |
Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity |
| title_full |
Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity |
| title_fullStr |
Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity |
| title_full_unstemmed |
Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity |
| title_sort |
preclinical pharmacokinetics and acute toxicity in rats of 5-{[(2e)-3-bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic acid: a novel 5-aminosalicylic acid derivative with potent anti-inflammatory activity |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/a964201dc07d49c3a8486aaa6196e02a |
| work_keys_str_mv |
AT maragutierrezsanchez preclinicalpharmacokineticsandacutetoxicityinratsof52e3bromo3carboxyprop2enoylamino2hydroxybenzoicacidanovel5aminosalicylicacidderivativewithpotentantiinflammatoryactivity AT aurelioromerocastro preclinicalpharmacokineticsandacutetoxicityinratsof52e3bromo3carboxyprop2enoylamino2hydroxybenzoicacidanovel5aminosalicylicacidderivativewithpotentantiinflammatoryactivity AT josecorreabasurto preclinicalpharmacokineticsandacutetoxicityinratsof52e3bromo3carboxyprop2enoylamino2hydroxybenzoicacidanovel5aminosalicylicacidderivativewithpotentantiinflammatoryactivity AT marthaceciliarosaleshernandez preclinicalpharmacokineticsandacutetoxicityinratsof52e3bromo3carboxyprop2enoylamino2hydroxybenzoicacidanovel5aminosalicylicacidderivativewithpotentantiinflammatoryactivity AT itziairenepadillamartinez preclinicalpharmacokineticsandacutetoxicityinratsof52e3bromo3carboxyprop2enoylamino2hydroxybenzoicacidanovel5aminosalicylicacidderivativewithpotentantiinflammatoryactivity AT jessicaelenamendietawejebe preclinicalpharmacokineticsandacutetoxicityinratsof52e3bromo3carboxyprop2enoylamino2hydroxybenzoicacidanovel5aminosalicylicacidderivativewithpotentantiinflammatoryactivity |
| _version_ |
1718411150848163840 |